CERVICAL CANCER

Authors

  • Mahmudjonova Sarvinoz Bahodirjon kizi, Akbarova Barchinoy Baqiyevna Kokand University Andijan Branch Faculty of Medicine, Department of Therapeutic Work, Andijan branch of Kokond University Teacher of Histology

DOI:

https://doi.org/10.55640/

Keywords:

Cervical cancer, Human Papillomavirus (HPV), Screening, Pap smear, Oncological prevention, Gynecological diseases, Chronic inflammation.

Abstract

Cervical cancer (CC) is one of the most common gynecological oncological diseases among women, with Human Papillomavirus (HPV) infection identified as its primary etiological factor [1, 2]. The disease often progresses asymptomatically in the early stages, making early screening and diagnosis critically important [3, 5]. Chronic inflammation, hormonal imbalances, immune system deficiency, and genetic factors also play a significant role in the development of CC [1, 7]. This article analyzes the epidemiology, pathogenesis mechanisms, diagnostic approaches, screening methods, and treatment strategies of CC [2, 4, 6]. Furthermore, preventive measures, including HPV vaccination and regular Pap smear tests, are discussed as ways to enable early detection of the disease and prevent severe progression [5, 6, 7, 8]. This work aims to systematically present scientific data on CC and enhance its clinical and preventive significance [3, 4].

Downloads

Download data is not yet available.

References

1.Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244–265.

2.Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890–907.

3.Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–e203.

4.Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical screening. Int J Cancer. 2006;119(5):1095–1101.

5.Denny L. Cervical cancer: prevention and treatment. Discov Med. 2012;14(75):125–131.

6.Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; ASCCP. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197(4):346–355.

7.Trimble CL, Frazer IH. Development of therapeutic HPV vaccines. Lancet Oncol. 2009;10(10):975–980.

Harper DM, Franco EL, Wheeler CM, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with HPV 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364(9447):1757–1765.

Downloads

Published

2026-01-28

Issue

Vol. 5 No. 01 (2026): Journal of Multidisciplinary Sciences and Innovations

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

How to Cite

CERVICAL CANCER. (2026). Journal of Multidisciplinary Sciences and Innovations, 5(01), 2264-2269. https://doi.org/10.55640/

Similar Articles

1-10 of 1005

You may also start an advanced similarity search for this article.